Matuzumab (formerly EMD 72000) is a humanized monoclonal antibody for the treatment of cancer. It binds to the epidermal growth factor receptor (EGFR) with high affinity.
Developed by Merck Serono in cooperation with Takeda Pharmaceutical, it is currently undergoing phase II clinical trials for the treatment of colorectal, lung and stomach cancer. On August 29, 2007, Merck Serono announced that the preliminary results of the colorectal cancer stu...
more
Matuzumab (formerly EMD 72000) is a humanized monoclonal antibody for the treatment of cancer. It binds to the epidermal growth factor receptor (EGFR) with high affinity.
Developed by Merck Serono in cooperation with Takeda Pharmaceutical, it is currently undergoing phase II clinical trials for the treatment of colorectal, lung and stomach cancer. On August 29, 2007, Merck Serono announced that the preliminary results of the colorectal cancer study were less than promising, and that further trials for treating this type of cancer may be abandoned. The results of the lung and stomach cancer studies are expected in 2008.
The antibody is directed against a protein, which is to be found in the diaphragms from human body cells to. This enzyme, a receptor tyrosine kinase with the designation EGFR receives chemical signals, growth factors so mentioned, which are in the [Gewebsflüssigkeit], and energizes then the cellulose change. Cancer cells have often a great many EGFR molecules in their...
less
